Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2762-2771

  Yung, W K Alfred ^a   Prados, Michael D ^a   Yaya Tur, Ricardo ^a   Rosenfeld, Steven S ^a   Brada, Michael ^a   Friedman, Henry S ^a   Albright, Robert ^a   Olson, Jeffrey ^a   Chang, Susan M ^a   O'Neill, Alison M ^a   Friedman, Allan H ^a   Bruner, Janet ^a   Yue, Nancy ^a   Dugan, Margaret ^a   Zaknoen, Sara ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; ASTHENIA; ASTROCYTOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RECURRENT CANCER; SKIN MANIFESTATION; SLEEP DISORDER; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0032855728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2762     Document Type: Article

References (39)

1. Burger PC, Vogel FS, Green SB, et al: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56:1106-1111, 1985
2. Nelson JS, Tsukada Y, Schoenfeld D, et al: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52:550-554, 1983
3. Levin VA, Silver P, Hannigan J, et al: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324, 1990
4. Rodriguez LA, Levin VA: Does chemotherapy benefit the patient with a central nervous system glioma? Oncology 1:29-36, 1987
5. Newlands ES, Blackledge GR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045:M&B 39831:NSC 362856). Br J Cancer 65:287-291, 1992
6. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new cytotoxic agent with promising activity against gliomas. Proc Am Soc Clin Oncol 12:176a, 1993 (abstr 499)
7. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29:940-942, 1993
8. ® (temozolomide) at first relapse in anaplastic astrocytoma (AA) patients. Proc Am Soc Clin Oncol 16:384a, 1997 (abstr 1370)
9. Newlands ES, O'Reilly SM, Glaser MG, et al: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32:2236-2241, 1996
10. Plowman J, Waud WR, Koutsoukos AD, et al: Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 54:3793-3799, 1994
11. Brada M, Moore S, Judson I, et al: A phase I study of SCH 52365 (temozolomide) in adult patients with advanced cancer. Proc Am Soc Clin Oncol 14:470a, 1995 (abstr A1521)
12. Clark AS, Deans B, Stevens MF, et al: Antitumor imidazotetrazines: 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 38:1493-1504, 1995
13. Tisdale MJ: Antitumor imidazotetrazines: XV. Role of guanine 06 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457-462, 1987
14. Meikle SR, Matthews JC, Brock CS, et al: Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study. Cancer Chemother Pharmacol 42:183-193, 1998
15. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
16. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
17. Groenvold M, Klee MC, Sprangers MA, et al: Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50:441-450, 1997
18. Osoba D, Aaronson NK, Muller M, et al: Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 34:263-278, 1997
19. Berger MS, Leibel SA, Bruner JM, et al: Primary central nervous system tumors of the supratentorial compartment, in Levin VA (ed): Cancer in the Nervous System. New York, NY, Churchill Livingstone, 1995
20. Brandes AA, Scelzi E, Zampieri P, et al: Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 20:364-367, 1997
21. Buckner JC, Brown LD, Kugler JW, et al: Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 82:430-435, 1995
22. Watne K, Hannisdal E, Nome O, et al: Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery 30:223-227, 1992
23. Hildebrand J, De Witte O, Sahmoud T: Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine: A phase II study. J Neurooncol 37:155-160, 1998
24. Hochberg F, Prados M, Russell C, et al: Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation: A phase I-II study. J Neurooncol 32:45-55, 1997
25. Yung WK, Harris MI, Bruner JM, et al: Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neurooncol 7:237-240, 1989
26. Prados M, Rodriguez L, Chamberlain M, et al: Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. Neurosurgery 24:806-809, 1989
27. Glass J, Hochberg FH, Gruber ML, et al: The treatment of odendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741-745, 1992
28. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1996
29. Rodriguez LA, Prados M, Silver P, et al: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420-2423, 1989
30. Newton HB, Junck L, Bromberg J, et al: Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40:1743-1746, 1990
31. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 9:860-864, 1991
32. Warnick RE, Prados MD, Mack EE, et al: A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19:69-74, 1994
33. Taylor SG, Nelson L, Baxter D, et al: Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). Cancer 36:1269-1276, 1975
34. Zander E, de Tribolet N, Wagenknecht L: Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation. Acta Neurochir 42:97-101, 1978
35. Levin VA, Crafts DC, Wilson CB, et al: BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. Cancer Treat Rep 60:243-249, 1976
36. Pouillart P, Mathe G, Thy TH, et al: Treatment of malignant glioms and brain metastases in adults with a combination of adriamycin, VM 26 and CCNU: Results of a phase II trial. Cancer 38:1909-1916, 1976
37. Levin VA, Hoffman WF, Pischer TL, et al: BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62:2071-2076, 1978
38. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain rumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10:766-771, 1992
39. Seiler RW, Vassella F, Markwalder H: Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors. Surg Neurol 11:237-242, 1979